CN103193645A - Medicine for treating cancer pain - Google Patents
Medicine for treating cancer pain Download PDFInfo
- Publication number
- CN103193645A CN103193645A CN2013101102968A CN201310110296A CN103193645A CN 103193645 A CN103193645 A CN 103193645A CN 2013101102968 A CN2013101102968 A CN 2013101102968A CN 201310110296 A CN201310110296 A CN 201310110296A CN 103193645 A CN103193645 A CN 103193645A
- Authority
- CN
- China
- Prior art keywords
- pain
- cancer pain
- cancer
- medicine
- treating cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention belongs to the technical field of medicine and particularly relates to application of compounds which have a structural formula defined in the specification and are high in optical purity in the preparation of medicaments for cancer pain. The invention also relates to pharmaceutical compositions containing the compounds.
Description
Technical field
The invention belongs to biomedicine field, be specifically related to 7S, 8R, 17S-trihydroxy--4Z, 9E, 11E, 13Z, 15E, the application of 19Z-docosahexenoic acid ring fourth (base) ester in preparation control cancer pain medicine.
Background technology
Pain is one of most common tumor related symptoms, and the definition of pain is " sensation and the emotional experience that are associated with actual or potential tissue injury or similar damage ".Cancer pain refers to the pain due to cancer, cancer related pathologies and the anticancer therapy.Cancer pain often is chronic pain.Pain is cancer patients's common sympton, the cancer patients of about 1/4 new diagnosis, 1/3 cancer patients who is receiving treatment and 3/4 patient with advanced cancer merge pain, cancer pain patient may survive several months or several years, if can not get appropriate pain management, the torment that the patient will bear the pain for a long time, and greatly influence their activity, sleep, mood and whole quality of life, pain caused by cancer is patient's personality integrity totteringly, arrange their self consciousness, causing lasting angor in the depth of one's heart.The misery that the cancer pain patient experiences on spirit, social mentality, mode of life, anxiety often surpass the pain that disease itself causes.
The World Health Organization (WHO) organizes palliative treatment expert, cancer pain expert to formulate the global guide of alleviating cancer pain nineteen eighty-two, i.e. famous three step analgesia therapies, although year pass by surplus in the of 20, the fundamental principle of three ladders still is widely accepted.WHO has determined the international benchmark of the pain therapy centered by opium kind analgesics, becomes the main flow of cancer pain treatment according to the therapeutics of this benchmark.Mild pain: first ladder of first-selected three ladders with the acetylsalicylic acid be representative NSAID (non-steroidal anti-inflammatory drug) (Nonsteroidal Antiinflammatory Drugs, NSAIDs); Moderate pain: first-selected weak opioid drug (be representative with the Cocaine), and can share non-steroidal anti-inflammatory drugs; Severe pain: first-selected strong opioid drug (be representative with the morphine), and can share non-steroidal anti-inflammatory drugs simultaneously.But side effects such as gastrointestinal damage or renal impairment take place in known nonopioid analgesic NSAIDs easily.Also know the opium kind analgesics morphine as representational side effect constipation arranged, feel sick, vomiting etc., also have owing to end administration suddenly or the minimizing dosage is brought Withrawal symptom.In addition, in cancer pain, also comprise neuropathic pain, owing to it is the pain that peripheral nerve or nervus centralis come to harm and take place, so the opiates effect is limited.In addition, when the morphine chronic administration, anti-opioid such as cholecystokinin or neuropeptide tyrosine strengthens, and causes the analgesic effect of morphine to descend, and forms the analgesia resistance.Replace existing non-opium and opium kind analgesics so need develop the anodyne of few side effects.
Summary of the invention
The objective of the invention is in order to remedy the deficiency of product on the market, a kind of novel cancer pain medicine is provided, described compound is as follows:
7S, 8R, 17S-trihydroxy--4Z, 9E, 11E, 13Z, 15E, 19Z-docosahexenoic acid ring fourth (base) ester, its structural formula is as follows:
Further, 7S, 8R, 17S-trihydroxy--4Z, 9E, 11E, 13Z, 15E, the application of 19Z-docosahexenoic acid ring fourth (base) ester in preparation control cancer pain medicine.
Compound of the present invention can be made pharmaceutically acceptable arbitrary formulation with one or more pharmaceutical excipients.
Embodiment
Embodiment 1. is alleviated the evaluation of cancer pain drug effect
Animal modeling: after the Animal Anesthesia, left side hind leg cropping, 75% ethanol disinfection femur and shin bone place skin, a skin incision that is about 0.5～1.0cm is cut along rectus femoris muscle tendon direction by the knee joint place, the careful kneecap that exposes, punch along the puncture of femur long axis direction at kneecap with disposable sterilized 1mL syringe needle earlier, change 10 μ L syringes then and enter marrow cavity of femur, the Lewis mice lung cancer cell solution that slowly injects 10 μ L (contains 3 * 10
5Individual cell) to femur.Live pin hole with the bone wax seal after injection finishes, clean wound, skin closure.Sham operated rats animal left side kneecap injects isopyknic physiological saline, and all the other operate same model group, and blank group is not carried out any processing.
Evaluation index: measure the thermal stimulus threshold of pain with the mouse hot plate method, earlier that hot plate temperature is constant in (50 ± 1) ℃, then mouse is placed on the hot plate, needed time value (s) is the threshold of pain of this animal when waiting to occur licking metapedes, every mouse is surveyed 3 times, 5min at interval gets 3 averages as the thermal stimulus threshold of pain (screen the basic threshold of pain and be used for experiment the animal of 10～30s) of this animal.
Medication and result: modeling beginning in the 8th day administration is used in conjunction 7d.Modeling the 14th day, the treatment group thermal stimulus threshold of pain obviously prolongs, and with model group significant difference (P＜0.05) is arranged relatively, sees Table 1.
Table 1. pain caused by cancer is respectively organized the variation of the mouse different time points thermal stimulus threshold of pain
Compare with time point with model group
△P＜0.05
Conclusion: table 1 data show that fully this compound has the effect of good control cancer pain, is compound 7S, 8R, 17S-trihydroxy--4Z, 9E, 11E, 13Z, 15E, the application of 19Z-docosahexenoic acid ring fourth (base) ester in preparation control cancer pain medicine provides solid foundation.
Claims (3)
1. compound as described below:
7S, 8R, 17S-trihydroxy--4Z, 9E, 11E, 13Z, 15E, 19Z-docosahexenoic acid ring fourth (base) ester, its structural formula is as follows:
2. compound according to claim 1 is characterized in that: the application in preparation control cancer pain medicine.
3. the described compound of claim 1 and one or more pharmaceutical excipients are made pharmaceutically acceptable arbitrary formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101102968A CN103193645A (en) | 2013-04-01 | 2013-04-01 | Medicine for treating cancer pain |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101102968A CN103193645A (en) | 2013-04-01 | 2013-04-01 | Medicine for treating cancer pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103193645A true CN103193645A (en) | 2013-07-10 |
Family
ID=48716482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101102968A Pending CN103193645A (en) | 2013-04-01 | 2013-04-01 | Medicine for treating cancer pain |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103193645A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103588668A (en) * | 2013-10-28 | 2014-02-19 | 史克勇 | Compound |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101265185A (en) * | 2008-04-22 | 2008-09-17 | 天津大学 | Process for preparing and separating methyl docosapentaenoate and methyl docosahexenoate |
| WO2011034887A2 (en) * | 2009-09-15 | 2011-03-24 | The Brigham And Women's Hospital, Inc. | A method for treating neuropathic pain |
-
2013
- 2013-04-01 CN CN2013101102968A patent/CN103193645A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101265185A (en) * | 2008-04-22 | 2008-09-17 | 天津大学 | Process for preparing and separating methyl docosapentaenoate and methyl docosahexenoate |
| WO2011034887A2 (en) * | 2009-09-15 | 2011-03-24 | The Brigham And Women's Hospital, Inc. | A method for treating neuropathic pain |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103588668A (en) * | 2013-10-28 | 2014-02-19 | 史克勇 | Compound |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sabatowski et al. | Pain treatment: a historical overview | |
| JP6205676B2 (en) | Independent analgesic sustained release drug delivery system and method for producing the same | |
| CN103588668A (en) | Compound | |
| CN103193647A (en) | Cancer pain treatment medicine with high optical purity | |
| CN103588672A (en) | Drug for treating cancer pain | |
| Sarkis et al. | Chronic dizocilpine or apomorphine and development of neuropathy in two rat models I: behavioral effects and role of nucleus accumbens | |
| JP6676062B2 (en) | Methods for treating cognitive decline | |
| CN103254077A (en) | Pain disease therapeutic agent | |
| Shaver et al. | A multimodal approach to management of suspected neuropathic pain in a prairie falcon (Falco mexicanus) | |
| CN103193643A (en) | Application of Resolvin D1 derivatives in cancer pain | |
| CN103193646A (en) | Medicine for treating pain | |
| CN103254079A (en) | Compounds for treating cancer pains | |
| CN103393714B (en) | Local anaesthetics pain relieving delay agent | |
| WO2020143746A1 (en) | Use of chlorogenic acid in preparing medicine or pharmaceutical composition for preventing or treating pain | |
| CN103265432A (en) | Drug for treating cancer pain | |
| CN103254080A (en) | Pain therapeutic drug | |
| CN107320674A (en) | A kind of Chinese medicine composition and its application | |
| CN103193645A (en) | Medicine for treating cancer pain | |
| CN103254081A (en) | Cancer pain therapeutic drug | |
| CN103550778B (en) | A kind of pharmaceutical composition for the treatment of affective disorder disease | |
| HANNA et al. | AN Evaluation OF DIHYDROMORPHINONE* IN TREATING POSTOPERATIVE PAIN | |
| CN103193644A (en) | Agent for treating pain diseases | |
| CN103265431A (en) | Compound for treating cancer pain | |
| CN103254078A (en) | Cancer pain drug | |
| Bieberly et al. | Long-acting injectable methadone (methadone-fluconazole) provides safe and effective postoperative analgesia in a randomized clinical trial for dogs undergoing soft tissue surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C05 | Deemed withdrawal (patent law before 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130710 |